# Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients

> **NCT03931928** · PHASE2 · COMPLETED · sponsor: **Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)** · enrollment: 356 (actual)

## Conditions studied

- Breast Cancer
- DCIS

## Interventions

- **DRUG:** (Z)-Endoxifen supplementation according to genotype
- **DRUG:** (Z)-Endoxifen supplementation according to plasma levels

## Key facts

- **NCT ID:** NCT03931928
- **Lead sponsor:** Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-10
- **Primary completion:** 2021-05-03
- **Final completion:** 2021-05-03
- **Target enrollment:** 356 (ACTUAL)
- **Last updated:** 2021-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03931928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03931928, "Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03931928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*